International BD

1. Track and analyze industry and market trends to assist in the completion of regular information intelligence.
2. Assist in the selection of potential cooperation and acquisition targets (including but not limited to R&D varieties, marketing varieties, platforms, etc.) in line with Simcere's development strategy, and provide information for investment and cooperation teams.
3. Provide supportive intelligence and information for the negotiation of potential transactions.
Pharmaceutical Science or other related science discipline
1522837228785 simcere新logo











我们时刻牢记“让患者早日用上更好药物”的企业使命。2007年以来,我们共提交了200多项囯内和PCT专利申请。目前已有超过10个创新药进入临床研究阶段,将极大的丰富和补充现有产品线。2015年,定位于聚焦转化医学关键技术, 助力创新药物研发的“转化医学与创新药物国家重点实验室”获国家科技部批准。2018年,先声药业成立23周年纪念日上,我们宣布先声上海(波士顿)创新中心正式启航。因此,我们连续多年被行业权威媒体评为“中国医药创新力十强企业”。


Simcere Pharmaceutical Group was founded on
March 28, 1995 with an enterprise mission to “discover and develop high-quality
medicines for patients.” Since its inception, we have grown from a registered
capital of 2.78 million to total assets of over 3 billion yuan, from a few
dozen people to a R&D-driven pharmaceutical enterprise with more than 3,000
talents, and from an annual tax of less than a million to about 500 million
yuan. We have ranked among “the top 100 Chinese Pharmaceutical Companies” for
consecutive years, and our growth goes beyond the numbers.


To fulfill our dream, we have progressed
through a string of strategic options, including but not limited to the development
of first generic products, merger and acquisition, the build-up of research
institute, an alliance with multinational corporations, and innovative research


At present, these efforts are bearing

In 2009, our montmorillonite powder product
successfully passed EU GMP certification and started exporting to Europe, a
milestone for 'Made in Simcere' for global markets. Currently, we are actively
implementing cGMP and EUGMP to transform all of our small molecule manufacture
sites to comply with international standards.


In recent years, Simcere has established
high-quality international cooperation through various partnership models. In
March 2018
the companys newly found precision medicine sector, Simcere Diagnotics, has
formed strategic partnership agreement with a Agena Bioscience
focusing on
expanding the use of Agena
s MassARRAY® System for companion diagnostics and pharmacogenetic
testing in China. In January 2018, Simcere obtained an exclusive license from
European biotech Merus to develop and commercialize in China 3 bispecific
antibodies utilizing Merus
s proprietary Biclonics® technology platform in the area of
immuno-oncology. In September 2017
Simcere entered into
Collaboration with Amgen to co-develop and commercialize a series of
biosimilars In China. Together with Bristol-Myers Squibb, we are conducting
Phase III trial for abatacept, a monoclonal antibody for treatment of
rheumatoid arthritis. These partnerships are a powerful testament to the fact
that Chinese pharmaceutical companies can collaborate with multinational
corporations to scale down R&D cost and accelerate R&D innovation in

We now own over 50 products that cover
Oncology, Cardiovascular and Cerebrovascular, Anti-infection, Rheumatology and
other therapeutic areas. We have three products (Endostar®, Sinofuan®, Iremod®)
that were the first-to-launch in the world, and six products (BICUN®
that were the first-in-class in China. Since 2007, we have submitted over 200
domestic and PCT patent applications. Over 10 innovative drugs are being
studied in clinical trials, which will broaden our current marketed product


In 2015, the Ministry of Science and
Technology designated one of our laboratories as the 'national key laboratory
for translational medicine and innovative drugs'. Simcere ranks among the 'Top
10 Chinese Companies in Pharmaceutical Innovation' in recent years. On March
28, 2018, Simcere announced the official establishment of Simcere Innovation
Center on the company's 23rd anniversary.


SIMCERE, we race with time to provide you
the better treatment.